Antibody drug conjugates for patients with breast cancer

Area of Science:

• Oncology
• Pharmacology
• Biotechnology

Background:

• Breast cancer treatment relies on receptor status (Hormone Receptor+, HER2+).
• Triple-negative breast cancer (TNBC) lacks these receptors, presenting a therapeutic challenge due to limited targeted options.
• Aggressive TNBC subtypes often lack targetable genomic alterations, necessitating novel treatment strategies.

Purpose of the Study:

• To review current FDA-approved antibody drug conjugate (ADC) therapies for breast cancer.
• To discuss investigational ADCs in advanced development stages.
• To explore the potential of ADCs across diverse breast cancer subtypes.

Main Methods:

• Literature review of FDA-approved ADCs for breast cancer.
• Analysis of clinical trial data for investigational ADCs.
• Examination of ADC targeting strategies for different breast cancer subtypes.

Main Results:

• Sacituzumab govitecan is an FDA-approved ADC for breast cancer.
• Several other ADCs are in advanced stages of clinical investigation.
• ADCs demonstrate potential therapeutic applications across various breast cancer subtypes, including TNBC.

Conclusions:

• ADCs represent a promising new class of therapeutics for breast cancer, particularly for TNBC.
• Targeted antigen delivery via ADCs may overcome limitations of traditional therapies.
• Future ADC advancements could potentially redefine breast cancer classification and treatment paradigms.